Market news

MILAN, September 28, 2026--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.

Tandem Diabetes Care (TNDM) has an average rating of overweight and mean price target of $29, accord

Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

Tandem Diabetes Care (TNDM) is back in focus after recent share price swings, with the stock closing at US$16.87. Investors are weighing mixed return figures and fresh financial data on revenue and profit. The share price of US$16.87 comes after a sharp 24.42% decline in the 1 month share price return. However, the 3 month share price return is up 17.64%, and the 1 year total shareholder return of 34.21% indicates momentum that has been building over a longer period, despite weaker 3 and 5...

Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.

Tandem Diabetes Care (NASDAQ:TNDM) highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product launches, including a tubeless version of its Tandem Mobi pump. Speaking at Canaccord’

Tandem Diabetes met Wall Street’s revenue and profit expectations in Q2, but the market responded negatively, likely reflecting investor caution around the pace of U.S. pump shipments and the near-term impact of the company’s business model transition. Management highlighted stronger pump shipment growth internationally and early traction from its new pharmacy channel in the U.S. CEO John Sheridan emphasized that the company’s ability to drive operational efficiencies and expand access to its te

Motley Fool Press Release.

Detailed price information for Tandem Diabetes Care (TNDM-Q) from The Globe and Mail including charting and trades.

Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) jumped 18.2% in the afternoon session after the company reported second-quarter results that showed improved profitability and a narrower-than-expected loss per share.

Detailed price information for Tandem Diabetes Care (TNDM-Q) from The Globe and Mail including charting and trades.

Tandem Diabetes Care (TNDM) has an average rating of overweight and mean price target of $29.26, acc

Tandem Diabetes Care (NASDAQ:TNDM) reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery techn

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of +8.82% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.8% year on year to $254.6 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $1.08 billion at the midpoint. Its GAAP loss of $0.31 per share was in line with analysts’ consensus estimates.

SAN DIEGO, August 06, 2026--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2026.

Detailed price information for Tandem Diabetes Care (TNDM-Q) from The Globe and Mail including charting and trades.

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. The U.S. market saw a strong rally in the second quarter, fueled by easing geopolitical tensions, falling oil prices, and robust corporate earnings. Growth stocks, especially in technology and […]

SAN DIEGO, July 28, 2026--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at Canaccord Genuity’s 46th Annual Growth Conference on Tuesday, August 11, 2026 at 1:30pm Eastern Time (10:30am Pacific Time).

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how healthcare technology stocks fared in Q1, starting with Tandem Diabetes (NASDAQ:TNDM).

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

In July 2026, Tandem Diabetes Care announced that its t:slim X2 insulin pump with Control-IQ+ technology is now compatible with Abbott’s FreeStyle Libre 3 Plus CGM in the UK, Switzerland, Sweden, Finland, and Italy, expanding CGM choice for pump users and enabling 15-day sensors with minute-by-minute glucose data. This integration strengthens Tandem’s ecosystem by pairing its advanced AutoBolus-enabled AID algorithm with one of Europe’s most widely used CGM platforms, potentially broadening...

Tandem Diabetes Care (TNDM) is back in focus after announcing that its t:slim X2 insulin pump with Control-IQ+ technology now connects with Abbott’s FreeStyle Libre 3 Plus CGM across five European countries. See our latest analysis for Tandem Diabetes Care. The Abbott tie up comes as Tandem Diabetes Care’s 1 year total shareholder return is down 1.15%, while the share price has fallen 28.49% year to date to $15.41. This suggests recent momentum has faded despite the product expansion...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is among the best get rich quick stocks to buy right now. On June 23, Kieran Ryan from Deutsche Bank started coverage on Tandem Diabetes Care, Inc. (NASDAQ:TNDM) with a Hold rating and a price target of $15.50. The firm highlighted the current transition to PayGo pharmacy, which it believes […]